U.S. Markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.8099%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.6460%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.3012%)
     
  • BTC-USD

    43,957.60
    -3,528.90 (-7.43%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Xylem (XYL) Provides Update on Q2 results, Confirms Deal Wins

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Xylem Inc. XYL provided its financial update for second-quarter results, considering the impacts of the coronavirus pandemic on its operational performance. Notably, the company’s share price increased 8.9% to eventually close at $73.33 yesterday.

Inside the Headlines

Xylem currently anticipates second-quarter adjusted earnings per share of 37-39 cents, whereas it reported 23 cents in the first quarter. Notably, on a reported basis, its quarterly earnings are likely to be 15-17 cents.

Also, for the second quarter, the company anticipates a year-over-year revenue decline of 14% (reported basis). Notably, for the quarter, the company’s organic revenues are expected to fall 12% on a year-over-year basis compared with a decline of 20-30% predicted earlier. It is worth mentioning that it recorded $1,123 million in the last reported quarter.

The Zacks Consensus Estimate for revenues is currently pegged at $999.7 million for the second quarter, which suggests a decline of 25.7% from the year-ago reported figure.

Moreover, Xylem communicated that it entered two significant contracts in the second quarter. Notably, it secured a large-scale irrigation project in India’s Telangana region, valued at about $115 million. The company anticipates realizing revenues from the deal over the next two to three years, commencing late in this year’s fourth quarter. In addition, it clinched a deal from Anglian Water in the U.K. for the deployment of software, smart metering and network solutions. This $90-million deal will yield revenue over the next five years, starting late this year.

Zacks Rank, Price Performance and Estimate Trend

The company, with a $13.2-billion market capitalization, currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Going forward, Xylem is expected to benefit from new products, innovation, growth initiatives and its focus on operational execution. However, weakness in end-markets caused by the coronavirus outbreak is predicted to impact its near-term results.

In the past three months, the company’s share price has increased 10.1% compared with the industry’s growth of 23.2%.

 


 

The Zacks Consensus Estimate for its earnings is pegged at $1.43 for 2020, marking a decline of 1.4% from the 60-day-ago figure.

Stocks to Consider

Some better-ranked stocks from the same space are Colfax Corporation CFX, Chart Industries, Inc. GTLS and The Middleby Corporation MIDD. All the companies currently carry a Zacks Rank #2 (Buy).

Colfax delivered a positive earnings surprise of 6.75%, on average, in the trailing four quarters.

Chart Industries delivered a positive earnings surprise of 1.41%, on average, in the trailing four quarters.

Middleby delivered a positive earnings surprise of 7.54%, on average, in the trailing four quarters.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Colfax Corporation (CFX) : Free Stock Analysis Report
 
Chart Industries, Inc. (GTLS) : Free Stock Analysis Report
 
The Middleby Corporation (MIDD) : Free Stock Analysis Report
 
Xylem Inc. (XYL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.